A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

NCT06019728 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry's Disease

Interventions

DRUG: AGALSIDASE BETA (GZ419828)
DRUG: Acetaminophen
DRUG: Diphenhydramine
DRUG: Dexamethasone
DRUG: Montelukast
DRUG: Loratadine
DRUG: Cetirizine
DRUG: Fexofenadine

Sponsor

Sanofi